<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36389746</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>21</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>22</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>HERV-W ENV antigenemia and correlation of increased anti-SARS-CoV-2 immunoglobulin levels with post-COVID-19 symptoms.</ArticleTitle><Pagination><StartPage>1020064</StartPage><MedlinePgn>1020064</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1020064</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2022.1020064</ELocationID><Abstract><AbstractText>Due to the wide scope and persistence of COVID-19&#xb4;s pandemic, post-COVID-19 condition represents a post-viral syndrome of unprecedented dimensions. SARS-CoV-2, in line with other infectious agents, has the capacity to activate dormant human endogenous retroviral sequences ancestrally integrated in human genomes (HERVs). This activation was shown to relate to aggravated COVID-19 patient&#xb4;s symptom severity. Despite our limited understanding of how HERVs are turned off upon infection clearance, or how HERVs mediate long-term effects when their transcription remains aberrantly on, the participation of these elements in neurologic disease, such as multiple sclerosis, is already settling the basis for effective therapeutic solutions. These observations support an urgent need to identify the mechanisms that lead to HERV expression with SARS-CoV-2 infection, on the one hand, and to answer whether persistent HERV expression exists in post-COVID-19 condition, on the other. The present study shows, for the first time, that the HERV-W ENV protein can still be actively expressed long after SARS-CoV-2 infection is resolved in post-COVID-19 condition patients. Moreover, increased anti-SARS-CoV-2 immunoglobulins in post-COVID-19 condition, particularly high anti-SARS-CoV-2 immunoglobulin levels of the E isotype (IgE), seem to strongly correlate with deteriorated patient physical function (r=-0.8057, p&lt;0.01). These results indicate that HERV-W ENV antigenemia and anti-SARS-CoV-2 IgE serology should be further studied to better characterize post-COVID-19 condition pathogenic drivers potentially differing in subsets of patients with various symptoms. They also point out that such biomarkers may serve to design therapeutic options for precision medicine in post-COVID-19 condition.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Gim&#xe9;nez-Orenga, Pierquin, Brunel, Charvet, Mart&#xed;n-Mart&#xed;nez, Perron and Oltra.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gim&#xe9;nez-Orenga</LastName><ForeName>Karen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Escuela de Doctorado, Universidad Cat&#xf3;lica de Valencia San Vicente M&#xe1;rtir, Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pierquin</LastName><ForeName>Justine</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Geneuro-Innovation, Bioparc La&#xeb;nnec, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brunel</LastName><ForeName>Joanna</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Geneuro-Innovation, Bioparc La&#xeb;nnec, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Charvet</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Geneuro-Innovation, Bioparc La&#xeb;nnec, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mart&#xed;n-Mart&#xed;nez</LastName><ForeName>Eva</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>National Health Service, Manises Hospital, Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perron</LastName><ForeName>Herv&#xe9;</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Geneuro-Innovation, Bioparc La&#xeb;nnec, Lyon, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>GeNeuro, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oltra</LastName><ForeName>Elisa</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Pathology, School of Health Sciences, Universidad Cat&#xf3;lica de Valencia San Vicente M&#xe1;rtir, Valencia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Traslacional San Alberto Magno, Universidad Cat&#xf3;lica de Valencia San Vicente M&#xe1;rtir, Valencia, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>37341-29-0</RegistryNumber><NameOfSubstance UI="D007073">Immunoglobulin E</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020077" MajorTopicYN="Y">Endogenous Retroviruses</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009103" MajorTopicYN="Y">Multiple Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007073" MajorTopicYN="N">Immunoglobulin E</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CFS</Keyword><Keyword MajorTopicYN="N">HERV-W</Keyword><Keyword MajorTopicYN="N">IgE</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">chronic fatigue syndrome</Keyword><Keyword MajorTopicYN="N">long COVID-19</Keyword><Keyword MajorTopicYN="N">post-COVID</Keyword><Keyword MajorTopicYN="N">serology</Keyword></KeywordList><CoiStatement>Authors JP, JB, BC and HP were employed by company GeNeuro-Innovation. HP, BC, JB and BC receive compensation from GeNeuro-Innovation for their work. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>17</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>10</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36389746</ArticleId><ArticleId IdType="pmc">PMC9647063</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2022.1020064</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Taquet M, Dercon Q, Luciano S, Geddes JR, Husain M, Harrison PJ. Incidence, co-occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study of 273,618 survivors of COVID-19. PloS Med (2021) 18(9):e1003773. doi:&#xa0;10.1371/journal.pmed.1003773</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1003773</ArticleId><ArticleId IdType="pmc">PMC8478214</ArticleId><ArticleId IdType="pubmed">34582441</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV, WHO Clinical Case Definition Working Group on Post-COVID-19 Condition . A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis (2022) 22(4):e102&#x2013;7. doi:&#xa0;10.1016/S1473-3099(21)00703-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00703-9</ArticleId><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Venkatesan P. NICE guideline on long COVID. Lancet Respir Med (2021) 9(2):129. doi:&#xa0;10.1016/S2213-2600(21)00031-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00031-X</ArticleId><ArticleId IdType="pmc">PMC7832375</ArticleId><ArticleId IdType="pubmed">33453162</ArticleId></ArticleIdList></Reference><Reference><Citation>Parker AM, Brigham E, Connolly B, McPeake J, Agranovich AV, Kenes MT, et al. . Addressing the post-acute sequelae of SARS-CoV-2 infection: a multidisciplinary model of care. Lancet Respir Med (2021) 9(11):1328&#x2013;41. doi:&#xa0;10.1016/S2213-2600(21)00385-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00385-4</ArticleId><ArticleId IdType="pmc">PMC8525917</ArticleId><ArticleId IdType="pubmed">34678213</ArticleId></ArticleIdList></Reference><Reference><Citation>Almenar-P&#xe9;rez E, S&#xe1;nchez-Fito T, Ovejero T, Nathanson L, Oltra E. Impact of polypharmacy on candidate biomarker miRNomes for the diagnosis of fibromyalgia and myalgic Encephalomyelitis/Chronic fatigue syndrome: Striking back on treatments. Pharmaceutics (2019) 11(3):126. doi:&#xa0;10.3390/pharmaceutics11030126</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics11030126</ArticleId><ArticleId IdType="pmc">PMC6471415</ArticleId><ArticleId IdType="pubmed">30889846</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong TL, Weitzer DJ. Long COVID and myalgic Encephalomyelitis/Chronic fatigue syndrome (ME/CFS)-a systemic review and comparison of clinical presentation and symptomatology. Medicina (Kaunas) (2021) 57(5):418. doi:&#xa0;10.3390/medicina57050418</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medicina57050418</ArticleId><ArticleId IdType="pmc">PMC8145228</ArticleId><ArticleId IdType="pubmed">33925784</ArticleId></ArticleIdList></Reference><Reference><Citation>Komaroff AL, Bateman L. Will COVID-19 lead to myalgic Encephalomyelitis/Chronic fatigue syndrome? Front Med (Lausanne) (2021) 7:606824. doi:&#xa0;10.3389/fmed.2020.606824</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2020.606824</ArticleId><ArticleId IdType="pmc">PMC7848220</ArticleId><ArticleId IdType="pubmed">33537329</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiech M, Chroscicki P, Swatler J, Stepnik D, De Biasi S, Hampel M, et al. . Remodeling of T cell dynamics during long COVID is dependent on severity of SARS-CoV-2 infection. Front Immunol (2022) 13:886431. doi:&#xa0;10.3389/fimmu.2022.886431</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.886431</ArticleId><ArticleId IdType="pmc">PMC9226563</ArticleId><ArticleId IdType="pubmed">35757700</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang JY, Zhang W, Roehrl VB, Roehrl MW, Roehrl MH. An autoantigen atlas from human lung HFL1 cells offers clues to neurological and diverse autoimmune manifestations of COVID-19. Front Immunol (2022) 13:831849. doi:&#xa0;10.3389/fimmu.2022.831849</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.831849</ArticleId><ArticleId IdType="pmc">PMC8987778</ArticleId><ArticleId IdType="pubmed">35401574</ArticleId></ArticleIdList></Reference><Reference><Citation>Matyushkina D, Shokina V, Tikhonova P, Manuvera V, Shirokov D, Kharlampieva D, et al. . Autoimmune effect of antibodies against the SARS-CoV-2 nucleoprotein. Viruses (2022) 14(6):1141. doi:&#xa0;10.3390/v14061141</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14061141</ArticleId><ArticleId IdType="pmc">PMC9228376</ArticleId><ArticleId IdType="pubmed">35746613</ArticleId></ArticleIdList></Reference><Reference><Citation>Meinhardt J, Radke J, Dittmayer C, Franz J, Thomas C, Mothes R, et al. . Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19. Nat Neurosci (2021) 24(2):168&#x2013;75. doi:&#xa0;10.1038/s41593-020-00758-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-020-00758-5</ArticleId><ArticleId IdType="pubmed">33257876</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan LY, Komarasamy TV, Rmt Balasubramaniam V. Hyperinflammatory immune response and COVID-19: A double edged sword. Front Immunol (2021) 12:742941. doi:&#xa0;10.3389/fimmu.2021.742941</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.742941</ArticleId><ArticleId IdType="pmc">PMC8515020</ArticleId><ArticleId IdType="pubmed">34659238</ArticleId></ArticleIdList></Reference><Reference><Citation>Macchietto MG, Langlois RA, Shen SS. Virus-induced transposable element expression up-regulation in human and mouse host cells. Life Sci Alliance (2020) 3(2):e201900536. doi:&#xa0;10.26508/lsa.201900536</Citation><ArticleIdList><ArticleId IdType="doi">10.26508/lsa.201900536</ArticleId><ArticleId IdType="pmc">PMC6977392</ArticleId><ArticleId IdType="pubmed">31964680</ArticleId></ArticleIdList></Reference><Reference><Citation>Gim&#xe9;nez-Orenga K, Oltra E. Human endogenous retrovirus as therapeutic targets in neurologic disease. Pharm (Basel) (2021) 14(6):495. doi:&#xa0;10.3390/ph14060495</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph14060495</ArticleId><ArticleId IdType="pmc">PMC8225122</ArticleId><ArticleId IdType="pubmed">34073730</ArticleId></ArticleIdList></Reference><Reference><Citation>Mi S, Lee X, Li X, Veldman GM, Finnerty H, Racie L, et al. . Syncytin is a captive retroviral envelope protein involved in human placental morphogenesis. Nature (2000) 403(6771):785&#x2013;9. doi:&#xa0;10.1038/35001608</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35001608</ArticleId><ArticleId IdType="pubmed">10693809</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito J, Sugimoto R, Nakaoka H, Yamada S, Kimura T, Hayano T, et al. . Systematic identification and characterization of regulatory elements derived from human endogenous retroviruses. PloS Genet (2017) 13(7):e1006883. doi:&#xa0;10.1371/journal.pgen.1006883</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1006883</ArticleId><ArticleId IdType="pmc">PMC5529029</ArticleId><ArticleId IdType="pubmed">28700586</ArticleId></ArticleIdList></Reference><Reference><Citation>van Horssen J, van der Pol S, Nijland P, Amor S, Perron H. Human endogenous retrovirus W in brain lesions: Rationale for targeted therapy in multiple sclerosis. Mult Scler Relat Disord (2016) 8:11&#x2013;8. doi:&#xa0;10.1016/j.msard.2016.04.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.msard.2016.04.006</ArticleId><ArticleId IdType="pubmed">27456869</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xfc;ry P, Nath A, Cr&#xe9;ange A, Dolei A, Marche P, Gold J, et al. . Human endogenous retroviruses in neurological diseases. Trends Mol Med (2018) 24(4):379&#x2013;94. doi:&#xa0;10.1016/j.molmed.2018.02.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2018.02.007</ArticleId><ArticleId IdType="pmc">PMC7185488</ArticleId><ArticleId IdType="pubmed">29551251</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W, Pandya D, Pasternack N, Garcia-Montojo M, Henderson L, Kozak CA, et al. . Retroviral elements in pathophysiology and as therapeutic targets for amyotrophic lateral sclerosis. Neurotherapeutics (2022). doi:&#xa0;10.1007/s13311-022-01233-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-022-01233-8</ArticleId><ArticleId IdType="pmc">PMC9587200</ArticleId><ArticleId IdType="pubmed">35415778</ArticleId></ArticleIdList></Reference><Reference><Citation>Balestrieri E, Minutolo A, Petrone V, Fanelli M, Iannetta M, Malagnino V, et al. . Evidence of the pathogenic HERV-W envelope expression in T lymphocytes in association with the respiratory outcome of COVID-19 patients. EBioMedicine (2021) 66:103341. doi:&#xa0;10.1016/j.ebiom.2021.103341</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2021.103341</ArticleId><ArticleId IdType="pmc">PMC8082064</ArticleId><ArticleId IdType="pubmed">33867312</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Montojo M, Nath A. HERV-W envelope expression in blood leukocytes as a marker of disease severity of COVID-19. EBioMedicine (2021) 67:103363. doi:&#xa0;10.1016/j.ebiom.2021.103363</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2021.103363</ArticleId><ArticleId IdType="pmc">PMC8116818</ArticleId><ArticleId IdType="pubmed">33993053</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjornevik K, Cortese M, Healy BC, Kuhle J, Mina MJ, Leng Y, et al. . Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science (2022) 375(6578):296&#x2013;301. doi:&#xa0;10.1126/science.abj8222</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abj8222</ArticleId><ArticleId IdType="pubmed">35025605</ArticleId></ArticleIdList></Reference><Reference><Citation>Pl&#x16b;me J, Galvanovskis A, &#x160;mite S, Romanchikova N, Zayakin P, Lin&#x113; A. Early and strong antibody responses to SARS-CoV-2 predict disease severity in COVID-19 patients. J Transl Med (2022) 20(1):176. doi:&#xa0;10.1186/s12967-022-03382-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-022-03382-y</ArticleId><ArticleId IdType="pmc">PMC9012069</ArticleId><ArticleId IdType="pubmed">35428263</ArticleId></ArticleIdList></Reference><Reference><Citation>Aydin Guclu O, Goktas SS, Gorek Dilektasli A, Acet Ozturk NA, Demirdogen E, Coskun F, et al. . A pilot study for IgE as a prognostic biomarker in COVID-19. Intern Med J (2022) 52(9):1495&#x2013;504. doi:&#xa0;10.1111/imj.15728</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imj.15728</ArticleId><ArticleId IdType="pmc">PMC9111421</ArticleId><ArticleId IdType="pubmed">35257465</ArticleId></ArticleIdList></Reference><Reference><Citation>Carruthers BM, Jain AK, De Meirleir KL, Peterson DL, Klimas NG, Lerner A, et al. . Myalgic encephalomyelitis/chronic fatigue syndrome: Clinical working case definition, diagnostic and treatment protocols. J Chronic Fatigue Syndr (2003) 11:7&#x2013;115.</Citation></Reference><Reference><Citation>Carruthers BM, van de Sande MI, De Meirleir KL, Klimas NG, Broderick G, Mitchell T, et al. . Myalgic encephalomyelitis: International consensus criteria. J Intern Med (2011) 270:3273&#x2013;8. doi:&#xa0;10.1111/j.1365-2796.2011.02428.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2796.2011.02428.x</ArticleId><ArticleId IdType="pmc">PMC3427890</ArticleId><ArticleId IdType="pubmed">21777306</ArticleId></ArticleIdList></Reference><Reference><Citation>Burckhardt CS, Clark SR, Bennett RM. The fibromyalgia impact questionnaire: development and validation. J Rheumatol (1991) 18(5):728&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">1865419</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivera J, Gonz&#xe1;lez T. The fibromyalgia impact questionnaire: a validated Spanish version to assess the health status in women with fibromyalgia. Clin Exp Rheumatol (2004) 22(5):554&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">15485007</ArticleId></ArticleIdList></Reference><Reference><Citation>Smets EM, Garssen B, Bonke B, De Haes JC. The multidimensional fatigue inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res (1995) 39(3):315&#x2013;25. doi:&#xa0;10.1016/0022-3999(94)00125-o</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-3999(94)00125-o</ArticleId><ArticleId IdType="pubmed">7636775</ArticleId></ArticleIdList></Reference><Reference><Citation>McHorney CA, Ware JE, Jr, Raczek AE. The MOS 36-item short-form health survey (SF-36): II. psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care (1993) 31(3):247&#x2013;63. doi:&#xa0;10.1097/00005650-199303000-00006</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005650-199303000-00006</ArticleId><ArticleId IdType="pubmed">8450681</ArticleId></ArticleIdList></Reference><Reference><Citation>Ovejero T, Sadones O, S&#xe1;nchez-Fito T, Almenar-P&#xe9;rez E, Espejo JA, Mart&#xed;n-Mart&#xed;nez E, et al. . Activation of transposable elements in immune cells of fibromyalgia patients. Int J Mol Sci (2020) 21(4):1366. doi:&#xa0;10.3390/ijms21041366</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21041366</ArticleId><ArticleId IdType="pmc">PMC7072917</ArticleId><ArticleId IdType="pubmed">32085571</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamouza R, Meyer U, Foiselle M, Richard JR, Wu CL, Boukouaci W, et al. . Identification of inflammatory subgroups of schizophrenia and bipolar disorder patients with HERV-W ENV antigenemia by unsupervised cluster analysis. Transl Psychiatry (2021) 11(1):377. doi:&#xa0;10.1038/s41398-021-01499-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41398-021-01499-0</ArticleId><ArticleId IdType="pmc">PMC8260666</ArticleId><ArticleId IdType="pubmed">34230451</ArticleId></ArticleIdList></Reference><Reference><Citation>Tirelli U, Taibi R, Chirumbolo S. Post COVID syndrome: a new challenge for medicine. Eur Rev Med Pharmacol Sci (2021) 25(12):4422&#x2013;5. doi:&#xa0;10.26355/eurrev_202106_26154</Citation><ArticleIdList><ArticleId IdType="doi">10.26355/eurrev_202106_26154</ArticleId><ArticleId IdType="pubmed">34227079</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, Haupert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. Global prevalence of post COVID-19 condition or long COVID: A meta-analysis and systematic review. J Infect Dis (2022) jiac136. doi:&#xa0;10.1093/infdis/jiac136</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac136</ArticleId><ArticleId IdType="pmc">PMC9047189</ArticleId><ArticleId IdType="pubmed">35429399</ArticleId></ArticleIdList></Reference><Reference><Citation>Choutka J, Jansari V, Hornig M, Iwasaki A. Unexplained post-acute infection syndromes. Nat Med (2022) 28(5):911&#x2013;23. doi:&#xa0;10.1038/s41591-022-01810-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01810-6</ArticleId><ArticleId IdType="pubmed">35585196</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A. The chronic fatigue syndrome: a comprehensive approach to its definition and study. international chronic fatigue syndrome study group. Ann Intern Med (1994) 121(12):953&#x2013;9. doi:&#xa0;10.7326/0003-4819-121-12-199412150-00009</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-121-12-199412150-00009</ArticleId><ArticleId IdType="pubmed">7978722</ArticleId></ArticleIdList></Reference><Reference><Citation>Jason LA, Cotler J, Islam MF, Sunnquist M, Katz BZ. Risks for developing myalgic Encephalomyelitis/Chronic fatigue syndrome in college students following infectious mononucleosis: A prospective cohort study. Clin Infect Dis (2021) 73(11):e3740&#x2013;6. doi:&#xa0;10.1093/cid/ciaa1886</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa1886</ArticleId><ArticleId IdType="pmc">PMC8664491</ArticleId><ArticleId IdType="pubmed">33367564</ArticleId></ArticleIdList></Reference><Reference><Citation>Patrick DM, Miller RR, Gardy JL, Parker SM, Morshed MG, Steiner TS, et al. . Lyme Disease diagnosed by alternative methods: A phenotype similar to that of chronic fatigue syndrome. Clin Infect Dis (2015) 61(7):1084&#x2013;91. doi:&#xa0;10.1093/cid/civ470</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/civ470</ArticleId><ArticleId IdType="pubmed">26082507</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam MH, Wing YK, Yu MW, Leung CM, Ma RC, Kong AP, et al. . Mental morbidities and chronic fatigue in severe acute respiratory syndrome survivors: long-term follow-up. Arch Intern Med (2009) 169(22):2142&#x2013;7. doi:&#xa0;10.1001/archinternmed.2009.384</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinternmed.2009.384</ArticleId><ArticleId IdType="pubmed">20008700</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim EJ, Ahn YC, Jang ES, Lee SW, Lee SH, Son CG. Systematic review and meta-analysis of the prevalence of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). J Transl Med (2020) 18(1):100. doi:&#xa0;10.1186/s12967-020-02269-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-020-02269-0</ArticleId><ArticleId IdType="pmc">PMC7038594</ArticleId><ArticleId IdType="pubmed">32093722</ArticleId></ArticleIdList></Reference><Reference><Citation>Joshee S, Vatti N, Chang C. Long-term effects of COVID-19. Mayo Clin Proc (2022) 97(3):579&#x2013;99. doi:&#xa0;10.1016/j.mayocp.2021.12.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mayocp.2021.12.017</ArticleId><ArticleId IdType="pmc">PMC8752286</ArticleId><ArticleId IdType="pubmed">35246288</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitfield E, Coffey C, Zhang H, Shi T, Wu X, Li Q, et al. . Axes of prognosis: Identifying subtypes of COVID-19 outcomes. AMIA Annu Symp Proc (2022) 2021:1198&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8861682</ArticleId><ArticleId IdType="pubmed">35308999</ArticleId></ArticleIdList></Reference><Reference><Citation>Michelen M, Manoharan L, Elkheir N, Cheng V, Dagens A, Hastie C, et al. . Characterising long COVID: a living systematic review. BMJ Glob Health (2021) 6(9):e005427. doi:&#xa0;10.1136/bmjgh-2021-005427</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjgh-2021-005427</ArticleId><ArticleId IdType="pmc">PMC8478580</ArticleId><ArticleId IdType="pubmed">34580069</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C, Liu L, Wang X, Liu Y, Wang M, Zhu F. HBV X protein induces overexpression of HERV-W env through NF-&#x3ba;B in HepG2 cells. Virus Genes (2017) 53(6):797&#x2013;806. doi:&#xa0;10.1007/s11262-017-1479-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11262-017-1479-2</ArticleId><ArticleId IdType="pubmed">28639221</ArticleId></ArticleIdList></Reference><Reference><Citation>Marston JL, Greenig M, Singh M, Bendall ML, Duarte RRR, Feschotte C, et al. . SARS-CoV-2 infection mediates differential expression of human endogenous retroviruses and long interspersed nuclear elements. JCI Insight (2021) 6(24):e147170. doi:&#xa0;10.1172/jci.insight.147170</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.147170</ArticleId><ArticleId IdType="pmc">PMC8783694</ArticleId><ArticleId IdType="pubmed">34731091</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodrigues LS, da Silva Nali LH, Leal COD, Sabino EC, Lacerda EM, Kingdon CC, et al. . HERV-K and HERV-W transcriptional activity in myalgic encephalomyelitis/chronic fatigue syndrome. Auto Immun Highlights (2019) 10(1):12. doi:&#xa0;10.1186/s13317-019-0122-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13317-019-0122-8</ArticleId><ArticleId IdType="pmc">PMC7065355</ArticleId><ArticleId IdType="pubmed">32257068</ArticleId></ArticleIdList></Reference><Reference><Citation>Natarajan A, Zlitni S, Brooks EF, Vance SE, Dahlen A, Hedlin H, et al. . Gastrointestinal symptoms and fecal shedding of SARS-CoV-2 RNA suggest prolonged gastrointestinal infection. Med (NY) (2022) 3(6):371&#x2013;387.e9. doi:&#xa0;10.1016/j.medj.2022.04.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medj.2022.04.001</ArticleId><ArticleId IdType="pmc">PMC9005383</ArticleId><ArticleId IdType="pubmed">35434682</ArticleId></ArticleIdList></Reference><Reference><Citation>Kremer D, Gruchot J, Weyers V, Oldemeier L, G&#xf6;ttle P, Healy L, et al. . pHERV-W envelope protein fuels microglial cell-dependent damage of myelinated axons in multiple sclerosis. Proc Natl Acad Sci USA (2019) 116(30):15216&#x2013;25. doi:&#xa0;10.1073/pnas.1901283116</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1901283116</ArticleId><ArticleId IdType="pmc">PMC6660731</ArticleId><ArticleId IdType="pubmed">31213545</ArticleId></ArticleIdList></Reference><Reference><Citation>Kremer D, Schichel T, F&#xf6;rster M, Tzekova N, Bernard C, van der Valk P, et al. . Human endogenous retrovirus type W envelope protein inhibits oligodendroglial precursor cell differentiation. Ann Neurol (2013) 74(5):721&#x2013;32. doi:&#xa0;10.1002/ana.23970</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.23970</ArticleId><ArticleId IdType="pubmed">23836485</ArticleId></ArticleIdList></Reference><Reference><Citation>Rolland A, Jouvin-Marche E, Viret C, Faure M, Perron H, Marche PN. The envelope protein of a human endogenous retrovirus-W family activates innate immunity through CD14/TLR4 and promotes Th1-like responses. J Immunol (2006) 176(12):7636&#x2013;44. doi:&#xa0;10.4049/jimmunol.176.12.7636</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.176.12.7636</ArticleId><ArticleId IdType="pubmed">16751411</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadadianpour A, Daniel J, Zhang J, Spiller BW, Makaraviciute A, DeWitt &#xc5;M, et al. . Human IgE mAbs identify major antigens of parasitic worm infection. J Allergy Clin Immunol (2022) S0091&#x2013;6749(22)00843-0. doi:&#xa0;10.1016/j.jaci.2022.05.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2022.05.022</ArticleId><ArticleId IdType="pmc">PMC9742163</ArticleId><ArticleId IdType="pubmed">35760390</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexiou A, H&#xf6;fer V, D&#xf6;lle-Bierke S, Gr&#xfc;nhagen J, Zuberbier T, Worm M. Elicitors and phenotypes of adult patients with proven IgE-mediated food allergy and non-immune-mediated food hypersensitivity to food additives. Clin Exp Allergy (2022). doi:&#xa0;10.1111/cea.14203</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cea.14203</ArticleId><ArticleId IdType="pubmed">35851700</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z, Shen Q, Chang H. Vaccines for COVID-19: A systematic review of immunogenicity, current development, and future prospects. Front Immunol (2022) 13:843928. doi:&#xa0;10.3389/fimmu.2022.843928</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.843928</ArticleId><ArticleId IdType="pmc">PMC9092649</ArticleId><ArticleId IdType="pubmed">35572592</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisnewski AV, Campillo Luna J, Redlich CA. Human IgG and IgA responses to COVID-19 mRNA vaccines. PloS One (2021) 16(6):e0249499. doi:&#xa0;10.1371/journal.pone.0249499</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0249499</ArticleId><ArticleId IdType="pmc">PMC8208542</ArticleId><ArticleId IdType="pubmed">34133415</ArticleId></ArticleIdList></Reference><Reference><Citation>Janssen NAF, Grondman I, de Nooijer AH, Boahen CK, Koeken VACM, Matzaraki V, et al. . Dysregulated innate and adaptive immune responses discriminate disease severity in COVID-19. J Infect Dis (2021) 223(8):1322&#x2013;33. doi:&#xa0;10.1093/infdis/jiab065</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab065</ArticleId><ArticleId IdType="pmc">PMC7928798</ArticleId><ArticleId IdType="pubmed">33524124</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang I, Pranata R. Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis. J Intensive Care (2020) 8:36. doi:&#xa0;10.1186/s40560-020-00453-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40560-020-00453-4</ArticleId><ArticleId IdType="pmc">PMC7245646</ArticleId><ArticleId IdType="pubmed">32483488</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee EE, Song KH, Hwang W, Ham SY, Jeong H, Kim JH, et al. . Pattern of inflammatory immune response determines the clinical course and outcome of COVID-19: unbiased clustering analysis. Sci Rep (2021) 11(1):8080. doi:&#xa0;10.1038/s41598-021-87668-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-87668-z</ArticleId><ArticleId IdType="pmc">PMC8044143</ArticleId><ArticleId IdType="pubmed">33850271</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>